JUNJİ UCHİDA, TOMOAKİ IWAİ, SHUNJİ NİSHİDE, KAZUYA KABEİ, NOBUYUKİ KUWABARA, TOSHİHİDE NAGANUMA, NORİHİKO KUMADA, YOSHİAKİ TAKEMOTO, TATSUYA NAKATANİ
Experimental and Clinical Transplantation - 2019;17(2):190-195
Objectives: Here, we report our 1-year follow-up data of stable ABO-incompatible kidney transplant recipients who converted from mycophenolate mofetil plus a standard dose of a calcineurin inhibitor to everolimus plus low exposure to calcineurin inhibitors. Materials and Methods: Our study included 17 recipients of ABO-incompatible kidney transplant procedures performed at our institution. At baseline and at 3 and 12 months after conversion, graft biopsies were performed to check for acute rejection and C4d deposition. Results: Treatment with everolimus was stopped due to adverse events in 8 patients (47.1%). Conversion to everolimus with calcineurin inhibitor minimization did not induce acute rejection or C4d deposition at 3 and 12 months after conversion in ABO-incompatible kidney transplant recipients in whom everolimus was maintained or stopped within 1 year after conversion. Conclusions: Everolimus elicited no acute rejection and no C4d deposition, whether everolimus was maintained or stopped within 1 year after conversion, in ABO-incompatible kidney transplant recipients.
